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Abstract
Background: Atypical breast hyperplasias (AH) have a 10-year risk of progression to invasive cancer estimated at
4–7%, with the overall risk of developing breast cancer increased by ~ 4-fold. AH lesions are estrogen receptor
alpha positive (ERα+) and represent risk indicators and/or precursor lesions to low grade ERα+ tumors. Therefore,
molecular profiles of AH lesions offer insights into the earliest changes in the breast epithelium, rendering it
susceptible to oncogenic transformation.
Methods: In this study, women were selected who were diagnosed with ductal or lobular AH, but no breast cancer
prior to or within the 2-year follow-up. Paired AH and histologically normal benign (HNB) tissues from patients were
microdissected. RNA was isolated, amplified linearly, labeled, and hybridized to whole transcriptome microarrays to
determine gene expression profiles. Genes that were differentially expressed between AH and HNB were identified
using a paired analysis. Gene expression signatures distinguishing AH and HNB were defined using AGNES and
PAM methods. Regulation of gene networks was investigated using breast epithelial cell lines, explant cultures of
normal breast tissue and mouse tissues.
Results: A 99-gene signature discriminated the histologically normal and AH tissues in 81% of the cases. Network
analysis identified coordinated alterations in signaling through ERα, epidermal growth factor receptors, and
androgen receptor which were associated with the development of both lobular and ductal AH. Decreased
expression of SFRP1 was also consistently lower in AH. Knockdown of SFRP1 in 76N-Tert cells resulted altered
expression of 13 genes similarly to that observed in AH. An SFRP1-regulated network was also observed in tissues
from mice lacking Sfrp1. Re-expression of SFRP1 in MCF7 cells provided further support for the SFRP1-regulated
network. Treatment of breast explant cultures with rSFRP1 dampened estrogen-induced progesterone receptor levels.
Conclusions: The alterations in gene expression were observed in both ductal and lobular AH suggesting shared
underlying mechanisms predisposing to AH. Loss of SFRP1 expression is a significant regulator of AH transcriptional
profiles driving previously unidentified changes affecting responses to estrogen and possibly other pathways. The gene
signature and pathways provide insights into alterations contributing to AH breast lesions.
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Background
Studies of premalignant breast lesions provide insights
into the mechanisms rendering the breast epithelium
susceptible to oncogenic transformation as well as identify
interventions that could prevent breast cancer. Atypical
hyperplasias (AH) develop in the terminal duct lobular
units of the breast and are further subdivided into either
atypical ductal hyperplasia (ADH) or lobular neoplasia
(LN). Lobular neoplasia encompasses atypical lobular
hyperplasia (ALH) and lobular carcinoma in situ (LCIS).
In addition, flat epithelia atypia (FEA) is a subtype of atyp-
ical ductal epithelium lacking architectural changes as
seen in ADH. The 10-year risk of progression to invasive
cancer is estimated to be 7% for all AH [1] with a cumula-
tive incidence approaching 35% at 30 years. The overall
risk of developing breast cancer is increased by ~ 4-fold
among women with atypia and is similar for both ductal
and lobular lesions [1, 2]. However, the risk is most pro-
minent among women with higher breast density [3]
suggesting that mechanisms underlying breast density
affect the progression of premalignant breast lesions. AH
lesions are most often positive for estrogen receptor alpha
(ERα+) and approximately 90% of tumors that develop
subsequently are ERα-positive. Thus, AH represent a pre-
cursor lesion to low-grade ERα-positive tumors. Selective
receptor modulators or aromatase inhibitors prevent
progression of AH to invasive carcinomas by about 60%
[4–6], further supporting an important role for estrogen
signaling in malignant progression of AH.
The expression of several genes and proteins have been
evaluated in AH and their relationship with risk of
progression. CK5/6 and ERα can aid the morphologic
interpretation of usual ductal hyperplasia and AH lesions
and increase the sensitivity of distinguishing among these
lesions [7, 8]. However, levels of ERα in AH detected by
immunohistochemical staining did not predict risk of
breast cancer [9]. The extent of Ki67 immunoreactivity in
normal breast tissue has been associated with an increased
risk of breast cancer [10]. Combined measures of proli-
feration, tumor suppressor activity, and inflammatory
signaling within AH, using immunohistochemical scoring
for Ki67, p16, and COX-2 respectively, have been used to
evaluate breast cancer risk [11]. Elevated levels of EZH2
were shown to be an early marker for progression of
preneoplastic lesions [12], while other studies identified
increases in DNA methylation within promoter elements
of tumor suppressor genes such as APC, DLEC1, HOXA1,
RASSF1A, and SFRP1 [13, 14]. Progressive methylation of
genes in early lesions was reported for RASSF1A and
RARB2, suggesting the potential value of these targets
[15]. Higher levels of estrogen receptor beta (ERβ) are
associated with a decreased risk of progression of AH
[16], suggesting that selective agonists of ERβ may offer
potential therapy for chemoprevention. Gene expression
profiles have also been used to identify early changes in
AH as well as adjacent tumors [17, 18]. These studies
suggest the presence of molecular changes within breast
epithelial cells associated with the transition to AH and
risk of progression to breast cancer.
In the present study, patients diagnosed with AH and
no history of breast cancer (prior to or within the 2-year
follow-up after AH diagnosis) were selected. Laser cap-
ture microdissection was used to collect both histologi-
cally normal benign epithelium (HNB) and AH tissues
from each patient. The complete transcriptome was
evaluated by microarray, and gene expression patterns
were used to define signatures that distinguish AH
lesions from HNB tissues. Although ADH and LN tis-
sues have distinct morphologic features, they did not
form distinct clusters based on gene expression patterns
suggesting that these premalignant lesions share under-
lying alterations in transcriptional programs. Pathway
analyses identified genes encoding ERα, epidermal
growth factor receptors (ERB-B), and androgen receptor
(AR) as central nodes in the expression profiles. ERB-B2
and WNT signaling pathways were also strongly over-
represented among the genes differentially expressed in
AH. As methylation and loss of SFRP1 expression had
been associated with premalignancy, we determined if it
may be responsible for altered expression of a subset of
genes altered in AH. Knock down of SFRP1 expression
in normal breast epithelial cells (76N-Tert) identified 13
genes within the AH signature that had not previously
been connected to SFRP1. SFRP1-regulated genes were
also observed in mammary tissue from mice bearing
deletion of the Sfrp1 gene. Re-expression of SFRP1 in an
ERα-positive breast cancer cell line (MCF7), which has
lost expression of the endogenous SFRP1 gene, had the
opposite effect providing additional confirmation of an
SFRP1-regulated gene network. Antagonism of estrogen-
induced responses in progesterone receptor levels was
demonstrated by addition of recombinant SFRP1 to
human breast explant cultures. These findings demon-
strate that SFRP1 expression is diminished in AH re-
sulting in deregulation of a larger program of genes and
loss of restraint on ERα signaling which may contribute
to development of premalignant breast lesions.
Methods
Patient specimens
This is a retrospective study using formalin-fixed and
paraffin-embedded (FFPE) archival tissue blocks. A search
of pathology electronic files (CoPath) included patients
with isolated AH lesions (atypical ductal hyperplasia, flat
epithelial atypia, atypical lobular hyperpalsai, classic type
lobular carcinoma in-situ) on core biopsy with subsequent
excisional biopsy, isolated AH lesions on primary exci-
sional biopsies, and reduction mammoplasties. Exclusion
Gregory et al. Breast Cancer Research           (2019) 21:76 Page 2 of 18
criteria included patients with a prior history of breast
cancer or breast cancer within 2 years of initial AH diag-
nosis or insufficient AH lesion on subsequent excision.
Original diagnoses were supported by at least two pa-
thologists. A subspecialized breast pathologist (GMC)
reviewed all cases retrieved for the study for concordance
of original diagnosis. Cases that, upon review by GMC,
did not meet histopathologic criteria for AH (ductal or
lobular) were excluded. Characteristics of patients and
diagnoses are in Table 1. Patient 14 was found to have
a diagnosis of severe ADH bordering on ductal car-
cinoma in situ (low grade) upon review of original slide
material. Institutional Review Board approval was ob-
tained from Baystate Health, Springfield, MA (protocol
number 182463).
Microscopic evaluation
Atypical hyperplasias (AH) arise in the terminal duct
lobular units of the breast and are divided into ductal
and lobular subtypes based on cytomorphologic character-
istics. Ductal lesions included in the study are atypical
ductal hyperplasia (ADH) and flat epithelial atypia (FEA);
lobular lesions included atypical lobular hyperplasia
(ALH) and/or classic lobular carcinoma in situ (LCIS),
representing a spectrum and also known as lobular
neoplasia. Subjects with either ductal or lobular atypia
were included in the analysis to assess differences in tran-
scriptional features. Areas of AH and benign ducts/lobules
were marked for microdissection by the breast pathologist.
RNA of sufficient quantity and quality was obtained from
21 AH lesions (from 20 patients). The tissues included 8
lobular lesions (ALH and/or LCIS), 11 ductal lesions
(ADH and/or FEA), and 2 that were a mixture of ductal
and lobular lesions. All subjects were female; the mean
age was 51.9 years (SD = 7.9 years).
Analysis of RNA integrity
The integrity of RNA in tissue sections was assessed by
amplifying 5′ fragment (nucleotides 1355–1472) and 3′
fragment (nucleotides 1650–1717) of the β-actin gene
(Additional file 2: Table S5) by quantitative RT-PCR (RT-
qPCR). An 8-μm section from each tissue block was placed
on a glass microscope slide in RNase-free conditions,
deparaffinized in 3 changes of xylene, and allowed to air-
dry under vacuum in a desiccator for 30min. The tissue
sample was scraped from the slide using a razor blade
directly into 150 μl digestion buffer containing 10 μl pro-
teinase K (miRNeasy FFPE Kit, Qiagen, Germantown, MD)
and incubated at 55 °C for 2 h. The samples were sub-
sequently incubated at 80 °C for 15min and transferred to
ice for 3min. The samples were centrifuged at 13,000×g for
20min, and the supernatant was transferred to new tubes.
The RNA was harvested following DNase digestion using
the miRNAeasy FFPE kit as described in the manufacturer’s
instructions (Qiagen). The cDNA was prepared using 100
ng total RNA, oligo dT primers, and the Transcriptor first
strand cDNA synthesis kit according to the manufacturer’s
instructions (Roche, Indianapolis, IN). Amplification of 5′
and 3′ β-Actin targets were performed using the KAPA
SYBR Fast Master Mix (Thermo Fisher, Waltham, MA)
containing 200 nM forward primer, 200 nM reverse primer,
and 5 μl cDNA. The conditions for mRNA amplification
were performed as follows: 40 cycles each of 1 cycle at
95 °C for 2min, 1 cycle at 95 °C for 15 s, and 1 cycle at
60 °C for 30 s; 1 cycle at 95 °C for 15 s, 1 cycle at 60 °C for
15 s, 20min ramp, and 1 cycle at 95 °C for 15 s. The Ct
value of the 3′ β-Actin target was subtracted from the Ct
value of the 5′ β-Actin target to determine the amplifi-
cation ratio. Specimens with ratios < 5 were used for
microdissection and transcriptome-wide profiling.
Table 1 Patient characteristics and array identifiers
Patient
ID
Age at
diagnosis
Diagnosis Affected
breast
Atypia
array ID
Benign
array ID
1 43 FEA Left JJ013 JJ014
2 46 LCIS Right JJ001 JJ002
3 47 ADH Right JJ005 JJ006
4 58 LCIS Left JJ015 JJ016
5 40 ADH, FEA Right JJ003 JJ004
6 63 ADH Left JJ007 JJ008
7 52 LCIS Right JJ009 JJ010
8 62 ADH, FEA Left JJ012 JJ011
9 46 LCIS Left JJ017 JJ018
10 40 ADH Right JJ019 NA@
11 49 ADH,
ALH
Left DJJ021 DJJ022
12 53 ALH, FEA Right DJJ023 DJJ024
13 53 LCIS Left DJJ025 DJJ026
14* 58 ADH Right DJJ027 DJJ028
15 60 LCIS, ALH Left DJJ029 DJJ030
16-
Block1**
52 ADH, FEA Right DJJ031 DJJ032
16-
Block2**
52 ADH, FEA Right DJJ033 NA***
18 47 ALH Left DJJ035 DJJ036
19 55 ALH Right DJJ037 DJJ038
20 70 ADH
severe
Right DJJ039 DJJ040
21 44 FEA Right DJJ041 DJJ042
22 50 ADH/FEA Left DJJ043 DJJ044
23 54 ADH/
DCIS
Left DJJ045 DJJ046
*Confirming records revealed that patient 14 followed up with DCIS in left
breast 6 months later
**For patient 16, two independent blocks with AH were analyzed separately
***There was insufficient benign tissue for Patient 16-Block2
@Defective array
Gregory et al. Breast Cancer Research           (2019) 21:76 Page 3 of 18
Microdissection and RNA isolation
The H&E stained sections of the AH samples were used
to estimate the total area for microdissection. A mini-
mum area of 10 × 106 μm2 was required to ensure a
minimum of 50 ng total RNA. Consecutive tissue sec-
tions (8-μm thick) were cut using RNase-free conditions
and mounted on membrane slides (MMI, Rockledge, FL)
. The first and every 4th section were H&E stained for
microscopic evaluation to confirm that AH tissue was
present in unstained microdissected areas. The AH le-
sion and benign glandular tissue were marked by a
breast pathologist (GMC) for microdissection. The be-
nign glandular areas were selected to be at least 1 cm
away from the AH lesion in the same tissue block or a
different block. The tissues on membrane slides were
deparaffinized in 3 changes of xylenes and allowed to
air-dry under a vacuum in a desiccator for 30 min prior
to laser capture microdissection. The unstained sections
were oriented for microdissection aided by landmarks
defined on the H&E stained slides. Areas to be microdis-
sected were circumscribed using MMI Cell Tools soft-
ware (Version Celltools-4.4 #261, Rockledge FL).
Microdissected AH and HNB tissues from each patient
were collected separately onto caps (MMI Inc., Rock-
ledge FL). The microdissected tissue was collected in
150 μl digestion buffer containing 10 μl proteinase K
(miRNeasey FFPE Kit, Qiagen), was kept overnight at
55 °C, and was stored at − 80 °C until further processing.
Total RNA was isolated from microdissected tissue
using the miRNeasy FFPE Kit (Qiagen) according to the
manufacturer’s instructions and quantified using a
NanoDrop™1000 (Thermo Fisher Scientific).
cDNA synthesis, amplification, and labeling
The Ovation® FFPE WTA System (NuGEN, San Carlos,
CA) was used to prepare amplified cDNA from FFPE-
derived total RNA because amplification is initiated at the
3′ end as well as randomly throughout the whole trans-
criptome in the sample which makes this system ideal for
amplification of RNA obtained from FFPE samples. Fifty
nanograms of RNA was used to prepare the cDNA accord-
ing to the manufacturer’s instructions. The cDNA was then
purified using columns from the QIAquick PCR Purifica-
tion kit (Qiagen). Buffer PB from the purification kit was
added to the cDNA reaction, loaded on to the column, and
centrifuged for 1min at 13,000×g. The flow through was
discarded, and 80% ethanol was added to the column and
centrifuged for 1min at 13,000×g. The 80% ethanol wash
step was repeated, and the purified cDNA was eluted with
nuclease-free water. An aliquot containing 5 μg of cDNA
was fragmented and labeled using the Encore® Biotin Mod-
ule (NuGEN) according to the manufacturer’s instructions.
The biotin-labeled cDNA was hybridized to Affymetrix 1.0
ST microarrays by Genome Explorations (Memphis, TN).
Analysis of microarray data
The data were normalized using the Single-Channel Array
Normalization (SCAN) and Universal exPression Codes
(UPC) methods from the BioConductor R package
“SCAN.UPC” [19]. This package produces standardized
expression measures that are used to estimate whether a
given gene or probe is active in a specific sample [20, 21].
ComBAT, an empirical Bayesian framework, was used to
adjust data for batch effects [22]. The normalized data are
available from the NCBI Gene Expression Omnibus
Repository [23] series record GSE118432. Limma [24] was
used to identify differentially expressed genes in a paired-
sample model, with HNB and AH samples paired by
patient. AH arrays JJ019 and DJJ033 were excluded from
the analysis because paired HNB data were not available
for these patients. A total of 1039 probesets were selected
with adjusted p < 0.05. Two methods were employed to
identify gene signatures distinguishing AH and normal
benign tissue. Agglomerative clustering was performed
using AGNES [25] to visualize gene expression pat-
terns. Prediction Analysis of Microarrays (PAM) was
used as an alternative approach to define a minimal
gene expression signature [26].
Network analysis
The differentially expressed probesets were mapped to
812 unique genes and used for network analysis [27]. In
cases where there were more than one probeset for a gene,
the data were averaged. Protein interaction networks were
constructed using the STRING database available within
the network analyst tool (http://www.networkanalyst.ca/).
Over-representation of KEGG pathways was determined,
and pathways were visualized using Cytoscape [28].
Analysis of genes dependent on SFRP1
The 76N-Tert cell line was derived from normal breast
epithelial cells [29] and expresses endogenous SFRP1.
Generation and cultivation of engineered human cell
lines (TERT-pSUPER, TERT-siSFRP1, MCF7-pCDNA,
MCF7-SFRP1) has been described previously [30–32].
Total RNA was extracted from cell lines using an acid-
phenol extraction procedure [33], according to the man-
ufacturer’s instructions (Trizol, Invitrogen, Carlsbad,
CA). Relative levels of mRNA were determined by using
the 1-Step Brilliant® SYBRIII® Green RT-qPCR Master
Mix Kit (Stratagene) containing 200 nM forward primer,
200 nM reverse primer, and 100 ng total RNA. The con-
ditions for cDNA synthesis and target mRNA amplifi-
cation were performed as follows: 1 cycle of 50 °C for 30
min, 1 cycle of 95 °C for 10 min, and 35 cycles each of
95 °C for 30 s, 55 °C for 1 min, and 72 °C for 30 s. Expres-
sion of each gene was normalized to levels of β-actin
mRNA. The PCR primer sequences used are described
in Additional file 2: Table S5.
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Animals
The study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
The protocol was approved by the Baystate Medical
Center Institutional Animal Care and Use Committee
(Permit Number: 132681). Ten-week-old female C57BL/
6-Sfrp1+/+ mice (n = 6) and C57BL/6-Sfrp1−/− mice
(n = 6) were individually housed in plastic cages with
food and water provided continuously and maintained
on a 12:12 light cycle. The Sfrp1 knockout allele has
been described previously [34, 35]. Mammary tissue was
collected from mice, flash-frozen, and stored at − 80 °C
until processed for RNA isolation and used to quantify
relative levels of transcripts by RT-qPCR using primers
described in Additional file 2: Table S5.
Human breast explant cultures
The tissue was aseptically minced and placed on Surgi-
foam gelatin sponges (Ferrosan, Sueborg, Denmark) in
60-mm tissue culture dishes containing phenol-red free
DMEM/F12 (Gibco) 2% charcoal stripped serum, insu-
lin, and gentamycin treated with vehicle (100% EtOH),
10 nM 17β-estradiol (E2; Sigma), or 10 nM E2 with 1 μg/
mL rSFRP. Explant cultures were maintained for 24 h in
5% CO2 air and subsequently formalin-fixed and
paraffin-embedded.
Progesterone receptor staining
Immunohistochemistry (IHC) was performed on a
DakoCytomation autostainer using the Envision HRP
Detection system (Dako, Carpinteria, CA). Mammary
tissue blocks were sectioned at 4 μm, deparaffinized
in xylene, rehydrated in graded ethanols, and rinsed
in Tris-phosphate-buffered saline (TBS). Heat-induced
antigen retrieval was performed in a microwave at
98 °C in 0.01 M citrate buffer. After cooling for 20
min, sections were rinsed in TBS and incubated with
rabbit polyclonal anti-PR 1:500, (Cell Signaling; #8757) for
30min at room temperature. Immunoreactivity was visu-
alized by incubation with diaminobenzidine for 5min. Tis-
sue sections were counterstained with hematoxylin,
dehydrated through graded ethanols and xylene, and
cover-slipped. Images were captured with an Olympus
BX41 light microscope using (SPOT™Imaging Solutions,
Detroit, MI). PR staining of epithelial cells was quantified
using ImageJ.
Statistical analyses
The mean expression of genes in parental cells (TERT-
pSUPER, MCF7-SFRP1) versus SFRP1 knockdown/overex-
pressing cells (TERT-siSFRP1, MCF7-SFRP1) and Sfrp1+/+
versus Sfrp1−/−mammary gland tissues were compared
using paired t tests.
Results
Expression patterns of biomarkers
AH lesions were classified as ductal or lobular based on
histomorphologic features (Fig. 1a). Immunohistochemi-
cal membranous expression of E-cadherin (encoded by
CDH1) has been used to differentiate ductal and lobular
hyperplasias, with a reduced level observed in lobular
lesions [36]. Consistent with these observations, ductal
lesions had overall higher levels of CDH1 mRNA com-
pared to the lobular lesions (Fig. 1b). AH tissues from
two patients had both lobular and ductal characteristics
and expressed levels of CDH1 mRNA similar to that in
ductal lesions. These results demonstrated that the
differential expression of CDH1 in lobular and ductal
AH was preserved in the linear amplification and de-
tection methods.
In an effort to define gene targets distinguishing AH
from HNB tissues, ComBAT and LIMMA-adjusted
mRNA expression levels were evaluated for several po-
tential biomarkers (Fig. 2). Levels of mRNA for ESR1
(encoding ERα) were increased in AH while KRT5
(encoding cytokeratin 5) was decreased (Fig. 2). SFRP1
(encoding secreted frizzled-related protein 1) was among
the most strongly downregulated genes in AH (Fig. 2).
These results validate selected genes that have been
shown to be differentially expressed in AH breast lesions
reaffirming the utility of the microarray expression
profiling methods. Expression of mRNA for COX2, P16/
INK4A, and KI67 (encoded by PTGS2, CDKN2A,
MKI67, respectively) and estrogen receptor beta (ERβ,
encoded by ESR2) were analyzed because prior studies
suggested these as biomarkers of AH at greater risk of
progression to breast cancer. We found that mRNA
levels for these genes did not differ significantly between
AH and HNB in either lobular or ductal subtypes of AH.
Expression signature for atypical hyperplasias
Gene expression profiles were used to derive a signature
of AH and to identify additional diagnostic biomarkers.
Gene expression patterns in normal breast epithelium
are quite variable among individuals which can obscure
the modest transcriptional alterations in premalignant
tissues. Therefore, a paired analysis of HNB and AH
within individuals was used to detect genes that are
differentially expressed in AH tissues. The paired ana-
lysis of AH and HNB tissues identified a total of 1039
differentially expressed probesets (LIMMA with adjusted
p values of < 0.05; Additional file 2: Table S1). By
increasing the threshold (adjusted p value < 0.005), the
signature was reduced to 99 probesets (Additional file 2:
Table S2) which were used for hierarchical clustering.
The data values are expressed as log2 ratios of HNB/AH
with red indicating higher expression compared to the
overall mean levels across tissues and blue decreased
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expression. Examples are GATA3, XBP1, and EVL for
which mRNA levels are increased in most of the AH
tissues. In contrast, ARRDC3, CXCL2, MAML2, and
SFRP1 are expressed in HNB, but expression is signifi-
cantly reduced in AH. Two major clusters were detected
that are enriched for AH or HNB patterns of gene expres-
sion (Fig. 3, designated “AH class” and “HNB class”). The
overall pattern observed was a decrease in expression of
genes in AH compared to the HNB class. Given the
substantial divergence in histologic features of lobular and
ductal lesions, it was anticipated that these would form
sub-branches. While sub-branches are evident in the AH
class, lobular and ductal lesions are distributed similarly in
these branches suggesting that ductal and lobular lesions
share a set of alterations driving their development.
While genes are selected to distinguish AH, misclassi-
fication was anticipated due to limitations in the specifi-
city of the gene signature and variations in molecular
features underlying AH lesions. The clustering identifies
2 patients for which the AH samples cluster with the
HNB. The lesion in patient 1 (array JJ013) was an FEA.
This is an intermediate lesion which may involve a
single-cell layer and bears some overlap in histological
features with normal tissue. Furthermore, the HNB
tissue from patient 1 (JJ014) is adjacent to the FEA
tissue in the cluster. The HNB tissue in patient 4 (JJ016)
is adjacent to the clustering of the LCIS lesion (JJ015)
suggesting that the molecular features are largely benign
despite the morphologic features. Conversely, the HNB
tissue for patient 15 clustered with the AH tissues
(DJJ030, DJJ029, respectively). The HNB and AH tissues
from patient 15 are adjacent to one another in the
clustering suggesting that the HNB tissue shared under-
lying molecular alterations despite the differences in
histologic features. The two samples from patient 15
form a branch in the cluster with the ADH from patient
14 (DJJ027). Patient 14 was diagnosed with DCIS in the
contralateral breast 6 months later raising the possibility
that the pattern of expression in this branch represents
increased likelihood for progression. In each of these
Fig. 1 Differential expression of CDH1 in AH and LN. a Examples of H&E stained sections of ductal and lobular lesions that were microdissected
and used for transcriptional profiling: (i) atypical ductal hyperplasia, (ii) flat epithelial atypia, and (iii) lobular carcinoma in situ. The magnification
for the main images are × 100 and × 600 for the insert. b Expression of CDH1 is shown for atypical hyperplasias that were diagnosed as ductal,
lobular, or contained components of both. The lobular atypical hyperplasias had overall lower levels of CDH1 expression compared to the ductal
atypical hyperplasias
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patients (1, 4, 15), the AH is adjacent to the HNB in the
cluster providing support for the reproducibility gene
expression patterns within individual patients. Overall,
the set of genes distinguishes HNB tissues for 81% of
patients (Fig. 3; 17/21 in “HNB class”), providing bio-
markers that can be used to aid discrimination of AH.
The data were also analyzed using the paired model
with blocking for the histopathology of lesions (ductal vs
lobular) to identify potential biomarkers. This identified
11 genes that differed consistently in mRNA levels
between HNB and AH (Fig. 4). Both KIT and PROM1
(encoding CD133) have been associated with stem cell
phenotypes and exhibit decreased expression in AH. The
chemokines CXCL2 and CCL28 along with secreted
leukocyte peptidase inhibitor (SLPI) participate in inflam-
matory responses and were among the differentially
expressed genes. While inflammation contributes to on-
cogenic progression, both were downregulated in atypia.
Similarly, the PI-3-kinase PIK3C2G was consistently de-
creased in AH along with genes involved in ion transport
(GABRP, SLC39A6). The increase in sorbitol dehydrogen-
ase (SORD) suggests metabolic changes, but the levels
Fig. 2 Normalized expression of genes implicated as potential biomarkers of AH. The relative levels of expression are reported for genes associated
with atypical hyperplasias. Only ESR1, KRT5, and SFRP1 had expression levels that differed significantly between histological normal benign tissues and
atypical hyperplasias. The colors indicate the diagnosis of lesions as ductal, lobular, or containing both
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were variable making it unlikely to be a reliable bio-
marker. The decreased levels of NKBIZ (encoding an
inhibitor of NFkB) together with increases in ESR1 may
combine to increase sensitivity to estrogen-stimulated
proliferation in AH.
Prediction Analysis of Microarrays (PAM) was used as
an alternate algorithm to identify gene expression signa-
tures. The ComBat-normalized data from the LIMMA
paired model (p < 0.05) was analyzed and identified a
PAM signature of 139 probesets (Additional file 2: Table
S3). The intersection of the AGNES and PAM signatures
identified 43 genes common to both methods (Table 2).
The keratins (KRT5 and KRT15) are among this group
as well as luminal markers (KIT, FOXA1). SFRP1 was
also identified in the signature of both prediction
algorithms. These independent methods for class
prediction provide a reduced set of biomarkers to aid
diagnosis of AH.
Pathway analysis
Gene expression patterns were overlaid onto protein-
protein interaction databases to detect pathways that are
altered in AH. Probesets that were differentially expressed
between the AH and HNB tissues (representing 812
genes) formed a zero-order network of 61 differentially
expressed genes (Fig. 5) that had direct interactions (61
seeds, 90 edges). The zero-order network reveals extensive
interactions of genes with ESR1, RHOB, AR, and EGFR
receptors (ERBB2, ERBB3, ERBB4) which form central
nodes. Expression of ERB-B receptors (ERBB2, ERBB3,
ERBB4) are elevated and have a total of 23 edges. In con-
trast, expression of ligands (TGFA, EGF, NRG1) and EGFR
Fig. 3 Hierarchical clustering of differentially expressed genes. Genes that were differentially expressed at p < 0.005 were selected and clustered
using AGNES. Two main clusters were defined that were enriched for either histologically normal benign tissue (HNB class) or histologically AH
(AH class). This gene set did not separate the ductal and lobular subtypes of AH. Two AH samples had expression patterns similar to the
histologically normal tissues. Samples JJ13 and JJ15 were diagnosed as FEA and LCIS, respectively. Both clustered adjacent to the histologically
normal tissue from the same patient (JJ14 and JJ16, respectively) suggesting that these are true benign tissues. In contrast, DJJ030 is histologically
normal tissue, but clusters adjacent to the LCIS tissue (DJJ029) from patient #15 suggesting that the tissue harbors genetic alterations driving the
gene expression but has not yet acquired the histological architecture of AH. The data values are expressed as log base 2 ratios of HNB/AH with
red indicating increased expression compared to the overall mean levels across tissues and blue decreased levels
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are decreased. RHOB levels were also elevated in AH
lesions and form a separate node with a group of genes
that are all downregulated. Increased expression of ESR1
is consistent with prior studies; however, the associated
increase in expression of KDM4B, XBP1, and NELB
suggests a subnetwork that may act in concert with
ERα. The androgen receptor (AR) is also elevated in
AH lesions and forms a subnetwork. Although FOXA1
and GATA3 are shown as interactors with only AR based
on the STRINGS database, both genes are known to col-
laborate with ERα.
The 1st-order networks were also analyzed to identify
broader pathways that may be over-represented and
indicate broader alterations in signaling pathways. The
major network had 306 genes/seeds that were differen-
tially expressed generating 3849 edges and 2364 nodes.
Additional subnetworks were detected but had only 1
differentially expressed seed in each. Within the major
Fig. 4 Differential expression of genes in histologically normal benign (HNB) and AH tissues. AGNES was used to select 99 genes that are most
strongly associated with AH. The distribution of normalized expression is shown for each of the top 11 genes. The colors indicate the diagnosis
of lesions as ductal, lobular, or containing both
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network with 306 seeds, there was over-representation
of five KEGG pathways with p < 10−25 (Table 3). The
alterations in ERBB2 and WNT signaling overlap exten-
sively with the pathways in cancer.
Genes in the signature regulated by SFRP1 expression
SFRP1 is best known for its antagonism of the WNT
pathway. However, it binds other proteins, such as
RANKL and thrombospondin, and its loss has been
demonstrated to affect signaling of other critical path-
ways involving ERα, TGFB receptor, and p53 through
less well-studied mechanisms. Therefore, loss of expres-
sion in AH may directly influence genes differentially
expressed in AH.
The 76N-Tert cells express SFRP1 and, therefore, were
used to test whether knockdown of SFRP1 (TERT-
siSFRP1) may drive a set of genes that are differentially
expressed in AH. The levels of SFRP1 in TERT-siSFRP1
cells are shown in Additional file 1: Figure S1. A total of
31 genes within the PAM signature (Additional file 2:
Table S3) were selected to test for differential expression
in the TERT-siSFRP1 vs TERT-pSUPER cells. In total, 6
genes with decreased expression in AH tissues (SLPI,
MAML2, ARRDC3, PIK3C2G, KRT15, CXCL2) were also
decreased by knockdown of SFRP1 (TERT-siSFRP1 cells;
Fig. 6a, b). Conversely, 6 genes for which mRNA levels
were increased in AH tissues (SGK3, FOXA1, AGR3,
MLPH, EVL, KDM4B) also had increased expression in
TERT-siSFRP1 cells compared to the TERT-pSUPER con-
trol cells (Fig. 6b). Among 19 other genes from the PAM
signature, mRNA levels for 16 genes were unaffected by
knockdown of SFRP1 while expression was the opposite
of that observed in AH for 3 genes. ERBB4 was also tested
because it is part of the zero-order network (Fig. 5) and
had been implicated in regulation by SFRP1. Knockdown
of SFRP1 resulted in increased ERBB4 mRNA consistent
with the higher levels in AH compared to HNB (Fig. 6a,
b). These results suggest that decreased expression of
SFRP1 alters a network of genes in AH.
We examined the expression of the 13 genes in mam-
mary tissues from Sfrp1−/− mice to confirm dependence
on SFRP1 and determine if the network is conserved
Table 2 Differentially expressed genes identified in both AGNES
and PAM signatures
AFFYMETRIX_EXON_ID Gene name
7903414 Amylase, alpha 1A (salivary) (AMY1A)
7927058 Unknown
7951133 Mastermind-like transcriptional coactivator 2
(MAML2)
7954208 Phosphatidylinositol-4-phosphate 3-kinase
catalytic subunit type 2 gamma (PIK3C2G)
7963427 Keratin 5 (KRT5)
7976726 Enah/Vasp-like (EVL)
7977621 NDRG family member 2 (NDRG2)
7978706 Forkhead box A1 (FOXA1)
7989501 Carbonic anhydrase 12 (CA12)
7996027 C-X3-C motif chemokine ligand 1 (CX3CL1)
8015337 Keratin 15 (KRT15)
8022927 Solute carrier family 39 member 6 (SLC39A6)
8024909 Lysine demethylase 4B (KDM4B)
8041644 Pleckstrin homology, MyTH4 and FERM
domain containing H2 (PLEKHH2)
8075182 X-box binding protein 1 (XBP1)
8086607 Lactotransferrin (LTF)
8094441 Solute carrier family 34 member 2 (SLC34A2)
8095110 KIT proto-oncogene receptor tyrosine
kinase (KIT)
8100994 C-X-C motif chemokine ligand 2 (CXCL2)
8106098 Microtubule-associated protein 1B (MAP1B)
8108873 Rho GTPase activating protein 26 (ARHGAP26)
8109926 Gamma-aminobutyric acid type A receptor
pi subunit (GABRP)
8111932 C-C motif chemokine ligand 28 (CCL28)
8113073 Arrestin domain containing 3 (ARRDC3)
8117120 Inhibitor of DNA binding 4, HLH protein (ID4)
8119076 Unknown
8121861 Nuclear receptor coactivator 7 (NCOA7)
8124144 DEK proto-oncogene (DEK)
8127234 Dystonin (DST)
8130556 Uncharacterized LOC100129518
(LOC100129518)
8136347 Caldesmon 1 (CALD1)
8145291 Solute carrier family 25 member 37 (SLC25A37)
8150076 Dual specificity phosphatase 4 (DUSP4)
8150428 Secreted frizzled-related protein 1 (SFRP1)
8152119 Neurocalcin delta (NCALD)
8155359 Contactin-associated protein-like 3B
(CNTNAP3B)
8155460 Contactin-associated protein-like 3
pseudogene 2 (CNTNAP3P2)
8155540 Contactin-associated protein-like 3B
Table 2 Differentially expressed genes identified in both AGNES
and PAM signatures (Continued)
AFFYMETRIX_EXON_ID Gene name
(CNTNAP3B)
8161460 Contactin-associated protein-like 3B
(CNTNAP3B)
8166447 Patched domain containing 1 (PTCHD1)
8168727 Unknown
8171297 Midline 1 (MID1)
8171921 Dystrophin (DMD)
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across species (Fig. 6c). Similar to AH in humans (Fig. 6a),
loss of Sfrp1 in mice resulted in reduced expression of 3
genes compared to the wild-type mice (Slpi, Arrdc3,
Pik3c2g) and increased expression of 3 genes (Foxa1, Erbb4,
Kdm4b). Therefore, a portion of the SFRP1-regulated
network was conserved in this mouse model. To explore if
re-expression of SFRP1 could reverse the changes, we used
MCF7 breast cancer cells which lack SFRP1 expression and
compared effects of over-expression (MCF7-SFRP1 vs
MCF7-pCDNA; see Additional file 1: Figure S1). Constitu-
tive expression of SFRP1 increased 5 genes (SLPI, MAML2,
ARRDC3, PI3KC2G, KRT15) that were downregulated in
AH and TERT-siSFRP1 cells and reduced expression of 3
genes (SGK3, FOXA1, AGR3) that were upregulated in AH
and TERT-siSFRP1 cells (Fig. 6d). These data demonstrate
the presence of an SFRP1-regulated gene network in both
human tissues and cell lines that is also conserved in mice.
Enhanced estrogen signaling and loss of SFRP1 expres-
sion are common features within the gene expression sig-
nature in AH, but it is unclear if these are related
mechanistically or are simply complementary alterations
acquired during development of AH. Therefore, we
wanted to determine if SFRP1 protein levels control re-
sponsiveness to estrogen stimulation. Explant cultures of
normal breast tissue from 5 subjects were treated with
17β-estradiol (E2) in the presence of recombinant SFRP1
(rSFRP) protein or vehicle control for 24 h to determine if
expression of progesterone receptor (PR) was altered
(Fig. 7). The percentage of breast epithelial cells express-
ing PR was increased in response to E2 treatment in the 5
patients. Addition of rSFRP1 suppressed the response to
E2 (p = 0.01). These results demonstrate that SFRP can
influence E2-stimulated responses in normal breast tissues
and that its loss in AH may affect estrogen signaling.
Discussion
The pathways disrupted in AH offer insights into the early
molecular changes that are associated with increased risk
of malignancy. Prior analyses of AH have most often uti-
lized regions of AH that co-exist with carcinomas [17, 18].
This approach was necessary because tissues from percu-
taneous core biopsies and excisional biopsies with AH in
Fig. 5 Zero-order network formed by genes that are differentially expressed in histologically normal benign (HNB) and AH tissues. A network of
protein interactions was constructed using 812 genes that were differentially expressed between AH and HNB tissues. The ERB-B genes (ERBB2,
ERBB3, ERBB4, EGFR) define a central node connected to three major nodes associated with elevated expression of ESR1, AR, and ROHB in AH
compared to HNB tissues. The data are presented as ratios with red indicating increased expression in AH tissues compared to HNB. Dotted lines
encompassing major nodes indicate zero-order subnetworks
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women without cancer are often exhausted for histo-
pathological diagnosis. The recovery and quality of RNA
from formalin-fixed, paraffin-embedded (FFPE) tissues is
poor and limits the methods for genome-wide transcrip-
tional profiling to 3′ ends of mRNA for prior studies [37].
However, AH adjacent to tumors may already harbor
alterations similar to the tumor cells [38] which can
confound results. To overcome these limitations, we opti-
mized methods for RNA isolation and amplification to
allow reproducible analysis of transcriptional profiles
using microdissected AH lesions from women without a
prior history of breast cancer.
Using these methods, we confirmed increases in mRNA
levels of ESR1 and decreases in KRT5 as were previously
reported using immunohistochemical detection of these
proteins [7], as well as differences in CDH1 (encoding
E-cadherin) in ductal and lobular AH [36]. Paired
analysis of AH and HNB tissues within individuals
identified a 99-gene signature that discriminated 90%
of the AH and 81% of the HNB (Fig. 3). HNB from 4 indi-
viduals clustered with the “AH class” which may reflect
false-positives. Alternatively, it may also reflect a limi-
tation of using tissue that is adjacent to AH lesions which
can harbor genetic alterations present in the AH [39, 40].
Field effects have been reported at margins of 2 cm [41].
This is especially likely for patient 15 for whom the HNB
clustered next to the AH suggesting similarity at the
molecular level. Conversely, AH from patients 1 and 4
were in the HNB class which may indicate false negatives,
but may also indicate lesions that express the morphologic
features of AH yet have a molecular signature more simi-
lar to HNB. The lesion from patient 1 was an FEA which
is consistent with a low potential for malignant progres-
sion. These inherent uncertainties in diagnosis lead to an
underestimate of the transcriptional changes in AH.
Conversely, the differences in expression detected using
the 99-gene signature reflect a robust set of biomarkers
that can aid concordance in the diagnosis of AH [42, 43].
Table 3 Pathways over-represented in the first-order 812 gene network
Pathway Total Expected Hits p value FDR
Pathways in cancer 310 80.9 197 6.53E−47 1.42E−44
ErbB signaling pathway 87 22.7 70 1.35E−26 1.47E−24
Chronic myeloid leukemia 73 19.1 62 3.38E−26 2.45E−24
HTLV-I infection 199 52 121 5.30E−26 2.78E−24
WNT signaling pathway 144 37.6 97 6.41E−26 2.78E−24
Focal adhesion 200 52.2 117 4.23E−23 1.53E−21
Pancreatic cancer 69 18 56 8.10E−22 2.51E−20
Neurotrophin signaling pathway 123 32.1 82 1.39E−21 3.78E−20
Prostate cancer 87 22.7 64 1.27E−20 3.07E−19
Colorectal cancer 49 12.8 43 1.21E−19 2.63E−18
Osteoclast differentiation 119 31.1 77 3.84E−19 7.58E−18
Acute myeloid leukemia 57 14.9 47 4.98E−19 9.01E−18
Hepatitis C 100 26.1 68 8.76E−19 1.46E−17
T cell receptor signaling pathway 98 25.6 67 1.02E−18 1.58E−17
Melanogenesis 101 26.4 68 2.02E−18 2.92E−17
Regulation of actin cytoskeleton 182 47.5 102 2.39E−18 3.24E−17
Chagas disease (American trypanosomiasis) 89 23.2 62 4.82E−18 6.15E−17
MAPK signaling pathway 265 69.2 132 1.51E−17 1.82E−16
B cell receptor signaling pathway 75 19.6 54 7.04E−17 8.04E−16
Gap junction 89 23.2 60 1.99E−16 2.16E−15
Renal cell carcinoma 60 15.7 46 2.51E−16 2.60E−15
Epstein-Barr virus infection 91 23.8 60 9.93E−16 9.79E−15
Cell cycle 124 32.4 74 1.37E−15 1.30E−14
Axon guidance 118 30.8 71 2.90E−15 2.62E−14
Toll-like receptor signaling pathway 97 25.3 62 3.02E−15 2.62E−14
Glioma 65 17 47 5.85E−15 4.88E−14
Herpes simplex infection 103 26.9 64 7.95E−15 6.39E−14
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Within the signature, there were increases in genes as-
sociated with the luminal (e.g., ESR1, GATA3, KRT18)
and decreases in genes associated with the basal breast
epithelium (e.g., KRT5, TP63, ACTA2). This may reflect
a clonal expansion neoplastic luminal cells in AH which
could result in a decrease in the apparent expression of
genes that are markers of the basal epithelium. However,
there were also significant decreases in genes associated
with the normal luminal epithelium. Immunolocalization
of c-KIT is reported in normal breast epithelial cells
[44, 45] with loss of c-KIT in low-grade breast cancers.
ELF5 has been associated with differentiation of the
luminal epithelium, and its expression is decreased
significantly in luminal A, luminal B, and HER2 subtypes
of breast cancer [46]. Levels of these genes associated with
luminal epithelium were decreased significantly in the AH
samples (Fig. 4; Additional file 2: Table S3). In addition,
increased levels of immunohistochemical staining for ERα,
GATA3, and FOXA1 proteins have been reported in early
breast lesions [8, 37, 47] which is consistent with in-
creased expression of mRNA detected in AH (Figs. 2, 3,
and 4, Additional file 2: Table S3). Therefore, the signature
is not solely due to the increase in luminal epithelium in
AH tissues. The expression analyses of AH may represent
more complex cellular phenotypes that are not charac-
teristic of either the basal or luminal cells within normal
breast tissues. Transcriptional profiling of mouse mam-
mary and human breast tissues have also revealed an
unexpected complexity of cellular identities and lineages
[48–50]. Therefore, it is possible that the gene signature in
AH may represent an enrichment of a subclass of breast
epithelial cells.
Models of breast progression generally support the
evolution of invasive ductal and lobular carcinomas
along two distinct lineages of lesions [51]. This is based
on the differences in genomic alterations and gene
expression profiles in invasive ductal and lobular carci-
nomas [52, 53]. A comprehensive analysis identified muta-
tional hallmarks distinguishing invasive lobular carcinomas
[54]. However, we failed to observe a distinction in expres-
sion profiles from ductal and lobular AH by hierarchical
clustering (Fig. 3). Similar numbers of AH were profiled for
Fig. 6 Expression of genes in AH and regulation by SFRP1. Genes associated with AH were identified by AGNES and PAM were examined for
regulation by SFRP1. a The relative expression of the genes in AH are shown. Green indicates genes with decreased expression in AH relative to
the HNB tissues and red indicates those with increased expression. b The effect of SFPR1 knockdown on gene expression was analyzed in a cell
line derived from normal breast epithelium and immortalized with telomerase (76NTERT cells). Relative levels of transcripts were determined by
RT-qPCR in TERT-siSFRP1 cells and the TERT-pSUPER vector control cells. c Similarly, mRNA levels of the genes was compared by RT-qPCR in
mouse mammary glands derived from Sfrp1−/− and control Sfrp1+/+ mice. d Breast cancer cells overexpressing SFRP1 (MCF7-SFRP1) and control
cells (MCF7-pCDNA) were also compared for relative levels of gene expression by RT-qPCR. The level of SFRP1 mRNA was normalized to the
amplification of ACTB mRNA, which was performed in parallel wells for each cell line or tissue. Bars represent mean ± SEM SFRP1/ACTB and are
expressed as relative expression of control TERT-pSUPER (b), control mice (c), and MCF7-pCDNA (d). Genes where loss of SFRP1 results in
decreased expression are shown in green, those increased are shown in red, and those which are unchanged are shown in white *p < 0.05,
**p < 0.01, and ***p < 0.001 (significantly different from control using Student’s t test)
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both the ductal and lobular histological classes, and expres-
sion of E-cadherin (CDH1) mRNA levels confirmed the
classifications. This raises the possibility that alterations in
a common set of pathways contribute to atypical hyper-
plasias in both ductal and lobular epithelial cells. The sub-
sequent alterations observed during progression toward
ductal and lobular carcinomas may be defined by vul-
nerabilities that differ in the ductal and lobular cell types.
The network analyses provide further insights into the
spectrum of molecular changes detected in AH and
render the breast epithelium at heightened risk of breast
cancer. Among genes that are differentially expressed in
AH (0-order network), we observed a network involving
ESR1, ERB-B receptors and AR/GATA3/FOXA1 (Fig. 5).
Prior studies examining transcriptional profiles of benign
hyperplasias also identified increased expression of ESR1
and ERBB genes [8, 47]. A study of matched normal,
early neoplasia and carcinoma from a cohort of 25
women identified elevated expression of ERBB2, FOXA1,
and GATA3 [37]. This study by Brunner et al. included
only 7 cases of early neoplasias without synchronous
cancer which likely limits the threshold for detecting
changes in AH. Nonetheless, they observed elevated
expression of KDM4B, XBP1, AR, MYB, and SPDEF in
early neoplasias compared to normal [37] which were
also elevated in our profile (Additional file 2: Table S1).
KDM4B and XBP1 are part of the interaction network
with ESR1 while SPDEF, FOXA1, GATA3, and MYB are
Fig. 7 Effect of SFRP1 on estrogen-induced expression of progesterone receptor (PR) in breast explant cultures. Normal breast tissues from
women undergoing reduction mammoplasty were placed in culture and treated with vehicle, 17β-estradiol (E2) or E2 together with rSFRP1 (E2 +
SFRP1). Immunohistochemical staining was used to detect cells expressing PR (brown chromogen). (a) Representative images from Subject 435
were captured at 400 × images for staining in ducts and lobule for one patient. (b) PR-stained cells were counted in each treatment group for 5
different subjects and the fold change in PR-positive cells is shown for each patient. Responses to E2 varied among individuals but SFRP1
diminished the effect of E2 in each case (E2 vs E2 +rSFRP1, p <0.01)
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linked to AR (Fig. 5). Therefore, our data is consistent
with and extends the information provided by prior
studies. As the samples used in our study were from AH
in patients without breast cancer, these genes define
alterations in pathways that may contribute to the forma-
tion of premalignant breast lesions. The prominent role of
estrogen signaling in the network is consistent with the
success of anti-estrogen treatments in preventing progres-
sion of AH to carcinomas [55, 56].
Signaling networks in AH may also include mRNAs and
proteins where levels are unchanged, but their activities
are stimulated by interactions with other proteins causing
post-translational modifications (e.g., by phosphorylation)
and formation of larger complexes. Therefore, the 1st-
order networks were also interrogated using KEGG path-
ways. This yielded a complex network of 306 genes and
again identified over-representation of ERB-B signaling.
WNT signaling was also found to be significantly over-
represented in AH (Table 3). While SFRP1 can antagonize
WNT signaling, it has been shown to also bind other
proteins such as RANKL and thrombospondin, as well as
affects signaling and responses via ERα, TGFβ, and p53
[30–32]. Furthermore, loss of SFRP1 is an early event
observed in the MCF10A progression series [57]. There-
fore, we tested whether loss of SFRP1 expression may
regulate a portion of the genes within the AH signature.
Inhibition of SFRP1 in immortalized normal breast epithe-
lial cells mirrored the changes in expression of 13 genes
that were differentially expressed in AH (Fig. 6b). Re-
expression of SFRP1 in MCF7 cells reversed the changes
in expression of 9 of the 13 genes tested (Fig. 6d). The
presence of an SFRP-regulated gene network was also
conserved in mouse mammary tissues (Fig. 6c). Consistent
with these findings, the Sfrp1−/− mice exhibit precocious
side-branching and hyperplasia of ductal/lobulo-alveolar
units [35]. Together, these data demonstrate a role for
SFRP1 in driving a portion of the signature found in AH.
Several of the SFRP1-regulated genes are involved in
signal transduction. Loss of SFRP1 expression had consist-
ent effects resulting in increased expression of FOXA1,
ERRB4, and KDM4B in both TERT-siSFRP1 cells and in
mouse mammary tissues. FOXA1 is a pioneer factor
which can open up chromatin to allow for access to
ERα transcriptional sites [58–60]. KDM4B is a histone
demethylase which is upregulated in ERα+ breast tumors
and can regulate the expression of both ERα and FOXA1
as well as modulate ERα and p53 signaling [61–64],
ERBB4/HER4 is critical for progesterone receptor (PR) ex-
pression [65] and has also been suggested to be respon-
sible for promoting an autocrine proliferation pathway
induced by estrogen [66, 67]. The increased expression of
FoxA1, Kdm4b, and Erbb4 a mammary glands of Sfrp1−/−
mice is consistent with the increased proportion of PR
expressing cells and proliferation [32].
Analysis of ERα activity and endogenous ERα targets
in our human cell lines also exhibited enhanced ERE
reporter activity when SFRP1 was knocked down and
repressed reporter activity when SFRP1 was re-expressed
[32]. To confirm previous studies suggesting SFRP1
control of estrogen-induced PR expression, we added
rSFRP1 to explants of normal breast tissue and demon-
strated tempered induction of PR protein by estrogen
(Fig. 7). Deletion of Sfrp1 in mice also resulted in en-
hanced estrogen-stimulated responses and occasional
hyperplasias, but was not sufficient for the development
of spontaneous mammary tumors [32, 35]. Therefore,
loss of SFRP1 expression appears to be a key driver lead-
ing to broader alterations in gene expression and permit-
ting increased signaling through ERα and derangements
in the ERB-B and WNT pathways as well.
Although considered a “benign” lesion because pro-
gression to invasive cancer is relatively low, AH presage
at least 40,000 breast cancer diagnoses annually [1, 68].
Therefore, intervention at this early stage offers the pos-
sibility of prevention of breast cancer. However, to
minimize overtreatment, it is important to identify bio-
markers discriminating the small subgroup of women
with AH for whom risk is sufficiently high to warrant
intervention. Molecular profiling of ductal carcinoma in
situ aids in identifying women who may omit radiation
following breast conserving surgery using a 12-gene
panel (7 biomarkers, 5 reference genes) [69, 70]. None of
these 7 biomarkers were detected among the 1039 genes
that were differentially expressed in AH compared to
histologically normal epithelium (Additional file 2: Table
S1). While the 99-gene signature discriminates AH
tissues (Fig. 3), the study is not able to access the utility
of the signature in assigning risk. Larger cohorts of pure
AH with follow-up of > 20 years for validation of predic-
tive signatures are needed to identify women with AH
who will benefit from interventions and reduce the
potential for overtreatment [2].
Conclusions
These results identify differentially expressed genes that
can be used to assist AH diagnoses. Loss of SFRP1
expression is a significant regulator of transcriptional
profiles in AH and acts, in part, to limit estrogen signa-
ling. These results support a broader role for SFRP1 in
coordinating estrogen-induced responses and WNT
signaling in normal breast epithelial cells.
Additional files
Additional file 1: Figure S1. The relative expression levels of SFRP1
mRNA are reduced in TERT-siSFRP1 cells and elevated in MCF7-SFRP1
cells. Total RNA was isolated from each cell line in triplicate for real-time PCR
analysis. The level of SFRP1 mRNA was normalized to the amplification of
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ACTB mRNA, which was performed in parallel wells for each cell line. Bars
represent mean ± SEM SFRP1/ACTB and are expressed as relative expression
of control cells (TERT-pSUPER or MCF7-pCDNA). ***p < 0.001 (significantly
different from control cell lines using Student’s t test). (JPG 182 kb)
Additional file 2: Table S1. Probesets that are differentially expressed
(1039 probesets). Table S2. Probesets selected by p < 0.005 used for
hierarchical clustering by AGNES (99 genes). Table S3. Probesets selected
by PAM (139 genes). Table S4. Zero-order gene network. Table S5.
Primers for RT-qPCR. (XLSX 204 kb)
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